Therapeutic efficacy of the benzoxazinorifamycin KRM-1648 against experimental Mycobacterium avium infection induced in rabbits.
The therapeutic efficacy of the benzoxazinorifamycin KRM-1648 was studied in an experimental rabbit infection system with avian Mycobacterium avium. The infected rabbits died from Yersin type infections, a peculiar type of experimental bovine tuberculosis characterized by a very rapid course, enlargement of the spleen and liver, and septic infection, 14 to 20 days after bacterial challenge, as evidenced by bacteremia and severe bacterial loads in the visceral organs. Histopathologic studies of the visceral organs of the infected rabbits revealed the development of numerous typical granulomatous lesions. This experimental rabbit infection system, features of which resemble certain features of disseminated M. avium complex infections in AIDS patients, was used to evaluate the therapeutic efficacy of KRM-1648, a newly synthesized benzoxazinorifamycin. KRM-1648 given orally at 25 and 50 mg/kg of body weight reduced the incidence and degree of bacteremia in infected rabbits and protected against subsequent death. Moreover, the drug allowed almost complete recovery of infected rabbits by week 7. KRM-1648 cleared infections in the lungs, liver, spleen, and kidneys and restored histopathologic features of healthy tissue in the visceral organs. KRM-1648 exhibited a more potent therapeutic effect against M. avium infection than rifampin and clarithromycin.
Emori
M
M
Department of Microbiology and Immunology, Shimane Medical University, Izumo, Japan.
Saito
H
H
Sato
K
K
Tomioka
H
H
Setogawa
T
T
Hidaka
T
T
D000818:Animals; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D001663:Bilirubin / Q000097:blood; D001835:Body Weight / Q000502:physiology; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin; D008099:Liver / Q000382:microbiology / Q000473:pathology; D008168:Lung / Q000382:microbiology / Q000473:pathology; D008297:Male; D009162:Mycobacterium avium; D011817:Rabbits; D012294:Rifamycins / Q000627:therapeutic use*; D013154:Spleen / Q000382:microbiology / Q000473:pathology; D013194:Staining and Labeling; D014379:Tuberculosis, Avian / Q000188:drug therapy* / Q000382:microbiology / Q000473:pathology
D000904:Antibiotics, Antitubercular; D012294:Rifamycins; C068980:KRM 1648; D001663:Bilirubin; D004801:Eosine Yellowish-(YS); D006416:Hematoxylin